HALO enters September with a striking divergence: options traders are leaning heavily bullish while short sellers have quietly rebuilt positions after a dramatic August earnings pop.
The options market is sending an unmistakably bullish signal. The put/call ratio has collapsed to 0.34 — well below both its 20-day mean of 0.71 and its 52-week low of 0.21. Call demand is running at nearly three times put volume. That's a sharp reversal from late August, when the PCR briefly touched 2.76 on August 24 and 2.56 on August 31, suggesting some traders were hedging into uncertainty. Those hedges appear to have been torn off. What's left is a market leaning firmly toward further upside.
The short story tells a more complicated tale. Short interest climbed nearly 4% over the week to 12.1% of the free float — roughly 14.3 million shares. That's a meaningful rebuild. For context, shorts were closer to 13.6 million shares in mid-August before the earnings print sent the stock up 23% in a single session on August 6. The post-earnings covering has been partially reversed, with bears rebuilding positions into the stock's 30% one-month rally. Yet the borrow market offers no signal that this short position is under stress. Cost to borrow is running at just 0.55%, barely changed on the week. Availability is wide — around 265% of current short interest, meaning there are more than two-and-a-half shares available to borrow for every one already lent out. Shorts can add freely. The ORTEX short score has drifted slightly lower this week, from around 68.6 to 66.9, suggesting the overall short setup is easing marginally even as raw share count ticks up.
The Street is broadly constructive but not without nuance. Following the August earnings beat, Leerink Partners upgraded HALO to Outperform and raised its target from $83 to $110. TD Cowen and HC Wainwright also lifted targets, to $105 and $115 respectively. Wells Fargo bumped its target from $75 to $95 while holding at Equal-Weight — essentially acknowledging the move without conviction on further upside. HC Wainwright reiterated its $115 Buy just this week. The consensus is four buys with a mean target near $115, implying modest upside from the current $107.72. The bull case centres on Halozyme's ENHANZE drug delivery platform — a royalty-generating technology that enables subcutaneous delivery for partners like Janssen, reducing the commercial and pipeline risk typical of pure-play biotech. The bear case focuses on execution risk in multiple myeloma and concentration in a handful of key partnerships. Forward EPS estimates rank in the 93rd percentile for year-on-year increase, and the PE multiple has expanded roughly 1.9 turns over the past 30 days to just under 11x — cheap for a platform business with this growth profile, which may explain why bulls remain committed.
On the institutional side, BlackRock remains the dominant holder at around 11.7% of shares, with a modest addition last reported. State Street and two Vanguard entities collectively hold another 14%. UBS Asset Management added more than 400,000 shares as of July 31 — one of the larger incremental moves among top holders. Los Angeles Capital Management stands out with a reported 1.25 million share addition, building to a 1.7% stake. No 13D activists are on the register; all major 13G holders are passive. The ownership base looks stable and incrementally growing into the rally.
The next catalyst is the Q3 earnings print, flagged for October 27. After the stock moved 23% the day after Q2 results and held most of that gain into the following week, the setup for October will be worth watching — particularly whether short sellers continue rebuilding positions into that date, and whether the wide borrow availability begins to tighten as event risk approaches.
See the live data behind this article on ORTEX.
Open HALO on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
